Smarter Solutions Series: Closing the Gap (Lesson 3)

Problem #3: Closing the Gap

AI-first biotech companies didn't get ahead by accident. They made specific structural choices that traditional pharma can learn from.

The gap is real. But it's closable if you're willing to change how you work, not just what tools you buy.

The Data:

76% of biotech organizations now use AI for literature review. 71% for protein structure prediction. 66% for scientific reporting. 58% for target identification. (Benchling 2026 Biotech AI Report)

50% of biotech report faster time-to-target today. 56% expect cost reductions within two years. (Benchling 2026)

But here's the gap: Adoption drops sharply in complex domains. Only 42% for generative design. 40% for biomarker analysis. 29% for ADME prediction. (Benchling 2026)

The limitation isn't the models. It's the data environment. 55% of organizations cite poor data quality and availability as the #1 reason AI pilots fail. (Benchling 2026)

1. They Put AI Leadership Inside R&D

30% of successful AI adopters place AI leadership directly inside R&D—not in IT. Another 35% use a hybrid model: centralized AI group for standards, specialists embedded in R&D teams. (Benchling 2026, Drug Discovery News 2026)

This proximity to the bench reduces handoffs and ensures AI tools fit into real-world experiments.

Traditional pharma puts AI in IT. Then wonders why scientists don't use it.

2. They Build "Prospective Data" From the Start

AI-first companies design experiments to generate AI-ready data. High-quality, well-annotated measurements that models can actually learn from.

Traditional pharma tries to retrofit AI onto messy legacy data. No amount of retroactive normalization fixes a poorly designed experiment.

Organizations with strong wet-dry lab integration are twice as likely to achieve high AI adoption—30% vs. 18%. (Benchling 2026)

3. They Upskill Internally, Not Hire Externally

67% of AI talent comes from internal upskilling. Only 21% from hiring tech specialists. (Benchling 2026)

AI-first companies run interdisciplinary sprint groups that test, validate, and fail fast. They embrace "build what differentiates, buy what scales."

Traditional pharma waits for IT to deploy tools that scientists never asked for.

4. They Treat AI as Infrastructure, Not a Project

Once AI models connect to data pipelines, lab workflows, or decision-support tools, they behave like infrastructure. They need monitoring, versioning, clear ownership, and change control. (Ardigen 2026) AI-first companies plan for this from day one. Traditional pharma treats AI as a pilot project that never graduates to production.

The Solution:

You can close the gap. But you have to make structural changes, not just buy tools. Here is what actually works:

Embed AI Where Work Happens

Don't centralize AI in IT. Embed AI specialists directly into commercial, clinical, and R&D teams. Your VP of Commercial Operations should have an AI lead on their team who understands launch workflows, not just algorithms.

Design for AI-Ready Data

Stop trying to fix legacy data. Start designing new data collection with AI in mind. Ask: "What would we need to measure for AI to optimize this process?" Then build that into your next campaign, trial, or launch.

Build Internal AI Literacy

Train your existing teams. Don't wait to hire AI experts. Run sprint groups. Test tools. Fail fast. Learn what works in your specific workflows before scaling.

Move AI from Pilot to Production

AI isn't a project. It's infrastructure. Treat it like your CRM or your analytics platform. Build monitoring, versioning, ownership structures. Plan for long-term maintenance, not one-time deployment.

The reality:

AI-first biotechs aren't smarter. They just don't have legacy systems and workflows to protect. You have infrastructure, resources, and market position they don't. But only if you're willing to reorganize around AI, not just add it on top of what you already do. The gap is closable. But not by buying the same tools. By changing how you work.

Need help embedding AI into your commercial or clinical workflows? Our AIdeation sessions help teams design AI-native processes that fit your organization. Contact us at FutureNova Health.

Sources: Benchling 2026 Biotech AI Report, Drug Discovery News 2026, Ardigen 2026